All News argenx SE

Equities

ARGX

NL0010832176

Market Closed - Euronext Bruxelles Other stock markets 09:05:13 29/04/2024 pm IST			5-day change	1st Jan Change
348.5 ^EUR	-0.23%		+3.38%	+1.46%

17/04	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
16/04	Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	17/04	MT
Argenx : argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	17/04	PU
Argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	16/04	GL
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	16/04	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	04/04	MT
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	28/03	AQ
Argenx : argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	27/03	PU
Argenx : argenx Announces Annual General Meeting of Shareholders on May 7, 2024	27/03	PU
Argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	27/03	GL
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease	27/03	CI
Argenx Announces Annual General Meeting of Shareholders on May 7, 2024	27/03	GL
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating	26/03	MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia	26/03	MT
Argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia	26/03	GL
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia	26/03	CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	21/03	MT
US Futures, European Stocks Rise After Fed Maintains Outlook	21/03	DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	13/03	MT
Argenx : argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	08/03	PU
Argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	08/03	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News argenx SE

Equities

ARGX

NL0010832176

All News

Filters